Revenue projection is hard to estimate. I had posted a message here, earlier in the year, an estimated analysis of what Rio Grande might have been selling before ENDV acquired the assets. It did appear to be a very significant amount. But then again RGN was on the downhill slide.
Opioid epidemic is the buzz term of the year. Lots of news about it. Even lawsuits popping up. This new avoidance of overly prescribing/using opioids can possibly open the doors wider for the acceptance/use of Sofpulse.
ENDV should market the heck out of Sofpulse for chronic wounds with the elderly. It is approved by Centers for Medicare and Medicaid. Let's have the Gov't become a big customer. Problem is changing the mindset of doctors and competing with pharmaceutical companies giving sales/use incentives to Doctors.
News 
Market Data 
Discover 
